Drug Approval | December 28, 2021
Optimus Pharma to manufacture and market molnupiravir
The company has developed the API in house at its R&D center in Hyderabad
The company has developed the API in house at its R&D center in Hyderabad
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
This product will be manufactured at Lupin's Goa facility in India
The Home Healthcare market is expected to be US $ 14.2 by 2025
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Flattish volume growth and subdued new launches were key factors for last month
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Subscribe To Our Newsletter & Stay Updated
